US 12,343,406 B2
Immunoreactant carrier
Cheol Hee Won, Seoul (KR)
Assigned to LEMONEX INC., Seoul (KR)
Appl. No. 17/265,692
Filed by LEMONEX INC., Seoul (KR)
PCT Filed Jun. 3, 2019, PCT No. PCT/KR2019/006682
§ 371(c)(1), (2) Date Feb. 3, 2021,
PCT Pub. No. WO2020/032366, PCT Pub. Date Feb. 13, 2020.
Claims priority of provisional application 62/714,874, filed on Aug. 6, 2018.
Claims priority of application No. 10-2019-0065620 (KR), filed on Jun. 3, 2019.
Prior Publication US 2021/0177988 A1, Jun. 17, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/69 (2017.01); C07K 14/54 (2006.01); C07K 14/55 (2006.01); C07K 16/28 (2006.01)
CPC A61K 47/6923 (2017.08) [C07K 14/5434 (2013.01); C07K 14/5437 (2013.01); C07K 14/5443 (2013.01); C07K 14/55 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A method for treating at least one of a cancer and an immune disease, the method comprising:
administering to a subject in need thereof an immunotherapeutic composition comprising an immunoreactive substance carrier loaded with an immunoreactive substance comprised of at least one of an antibody or cytokine, the immunoreactive substance carrier comprising:
expanded porous silica particles which carry the at least one of an antibody and cytokine,
wherein an average diameter of the expanded porous silica particles ranges from 150 to 1,000 nm, a Brunauer-Emmett-Teller (BET) surface area ranges from 200 to 700 m2/g, and a volume per g ranges from 0.7 to 2.2 ml; and
the expanded porous silica particles are characterized in that t, at which an absorbance ratio in the following Equation 1 becomes ½, is 24 hours or more:
At/A0  [Equation 1]
 wherein A0 is absorbance of the expanded porous silica particles measured by placing 5 ml of suspension containing 1 mg/ml of the expanded porous silica particles in a cylindrical permeable membrane having pores with a pore diameter of 50 kDa;
 15 ml of the same solvent as the suspension comes into contact with outside of the permeable membrane, and the inside/outside of the permeable membrane is horizontally stirred at 60 rpm and 37° C.;
 pH of the suspension is 7.4; and
 At indicates absorbance of the expanded porous silica particle measured after lapse of “t” hours since A0 was measured,
wherein an outer surface of the immunoreactive substance carrier is an outer surface of the expanded porous silica particle, and
the at least one of an antibody or cytokine is supported on the outer surface of the immunoreactive substance carrier and/or an inside of the pores.